| Literature DB >> 2880213 |
J Convit, P L Castellanos, A Rondon, M E Pinardi, M Ulrich, M Castes, B Bloom, L Garcia.
Abstract
In a randomised trial a combination vaccine consisting of live BCG together with killed leishmania promastigotes was compared with a standard antimonial regimen in 94 patients with localised cutaneous leishmaniasis. Three vaccinations over 32 weeks gave a similar cure rate (94%) to three 20-day courses of meglumine antimonate. In the immunotherapy group side-effects were few (5.8%) and slight whereas in the chemotherapy group they were frequent (52.4%) and often serious. Immunotherapy is a low-cost, low-risk alternative to chemotherapy in localised cutaneous leishmaniasis, applicable by primary health services in rural areas.Entities:
Mesh：
Substances：
Year: 1987 PMID： 2880213 DOI： 10.1016/s0140-6736(87)90116-4
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321